Meeting
2013 Gastrointestinal Cancers Symposium
Class III β-tubulin as a predictive marker for taxane-based first-line palliative chemotherapy in recurrent or metastatic gastric cancer.
Authors
Jun-Eul Hwang
Department of Hematology-Oncology, Chonnam Nationa
Jun-Eul Hwang , Dae-Eun Kim , Hyun-Jeong Shim , Woo Kyun Bae , Sang-Hee Cho , Ik-Joo Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr44)
DOI
10.1200/jco.2013.31.4_suppl.44
Abstract #
44
Poster Bd #
A44
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.
First Author: Fabiola Cecchi
Poster
2016 ASCO Annual Meeting
Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer.
First Author: Hongjae Chon
Poster
2015 Gastrointestinal Cancers Symposium
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial.
First Author: Gianluca Tomasello
Poster
2015 Gastrointestinal Cancers Symposium
Early tumor shrinkage (ETS) and deepness of response (DpR) in patients with metastatic esophageal cancer receiving a first-line treatment with DCF: Exploratory analysis of the JCOG0807.
First Author: Takashi Ura